Background. Antigametocyte-specific immune responses may regulate Plasmodium falciparum gametocyte density, providing the rationale for pursuing transmission-blocking vaccines (TBVs) that target gametocytes in the human host.
Despite an unprecedented increase in implementation of malaria control policies over the last 2 decades, malaria remains an overwhelming public health burden [1, 2] . Recent intensification of control efforts have escalated to calls for malaria elimination/eradication [3, 4] . This recent paradigm shift [5] requires new strategic goals, including the development of malaria vaccines that prevent forward parasite transmission.
Leading transmission-blocking vaccines (TBVs) [6] [7] [8] [9] [10] [11] are based on key gamete antigens produced in gametocytes that elicit antibodies in the human host. When ingested in a bloodmeal, these antigamete antibodies interfere/block gamete fertilization and ookinete invasion in the mosquito. However, an alternative approach to malaria TBV development exists.
Residents of endemic areas develop naturally acquired immunity with age, a phenomenon shown to limit asexual parasitemia and clinical disease [12] . Epidemiologic studies indicate that gametocyte prevalence declines with age more precipitously than the prevalence of asexual parasites [13, 14] , prompting investigators to hypothesize that antigametocyte-specific immune responses capable of controlling gametocyte density exist and that these responses are distinct from responses that control asexual parasitemia. Antibodies in the sera of naturally exposed individuals capable of recognizing erythrocytes infected with mature stage V gametocytes have been demonstrated in some [15] [16] [17] but not all studies, requiring further investigation. This evidence suggests that human antibodies may limit gametocytemia, but the targets of these putative protective responses remain unknown. To reify these observations into a TBV identification program, we used our differential, whole-proteome screening method [18, 19] to interrogate the Plasmodium falciparum gametocyte stage proteome with plasma and parasitological data from an immunoepidemiologic treatment-reinfection study. Our a priori hypothesis was that a subset of gametocyte-specific antigens identified would elicit gametocyte-controlling humoral responses.
SUBJECTS, MATERIALS, AND METHODS

Study Population
This study is a secondary analysis of epidemiologic data and blood samples collected in 1997 as part of a treatment-reinfection study [20, 21] in Kenya. At time of sample collection, the entomological inoculation rate exceeded 300 infectious bites/ year [22] . Ethical approval was obtained from Walter Reed Army Institute of Research, the Kenyan Medical Research Institute, and Brown University.
Upon informed consent, 144 males (12-35 years) entered the study at the beginning of the high transmission (April 1997). Detectable parasitemia was eradicated in 143 participants with quinine sulfate and doxycycline. Blood films were obtained from each volunteer before treatment and weekly for 18 weeks after treatment. Malaria assessment, entomology measurements, blood collection, and hemoglobin electropheresis have been reported elsewhere [20, 21, 23, 24] .
Selection of Resistant and Susceptible Individuals
Using the mean gametocyte density of the 18 posttreatment blood films, we identified and pooled plasma from the 10 most resistant (low gametocytemia/resistant [RP]) and 10 most susceptible (high gametocytemia/susceptible [SP]) individuals after matching for potential confounding variables of age, hemoglobin phenotype (AA vs AS-sickle trait), hemoglobin level, asexual parasite density, frequency of asexual parasitemia, number of sulfadoxine-pyrimethamine doses, and mean week doses were administered.
Differential Screening of Complementary Deoxyribonucleic Acid Library
Using a P falciparum gametocyte stage complementary deoxyribonucleic acid (cDNA) expression library (MRA-101, MR4), we screened duplicate filters with RP and SP, according to the manufacturer's directions (Stratagene), using polyvalent antihuman immunoglobulin ([Ig] Sigma) for detection.
Expression and Purification of Recombinant Proteins
Parasite DNA from gametocyte-specific clones uniquely reactive with RP was excised with helper phage and sequenced, and identities were determined by nucleotide-based Basic Local Alignment Search Tool (BLAST) searches of GenBank or the P falciparum database (http://www.plasmodb.org). The open-reading frame (ORF) of identified clones was codon-optimized for bacterial expression, cloned into the plasmid pD451-SR (Atum), and expressed in the host strain BL21(DE3) (Novagen). Recombinant antigens were purified by fast-performance liquid chromatography as described [18, 25] (see Supplementary Methods).
Total Antigen-Specific Immunoglobulin Assays
Using recombinant antigens as targets, we performed multiplexed antigen-specific antibody assays [26] on plasma samples collected at the start of the high-transmission season (n = 143).
Recombinant antigens or bovine serum albumin (100 μg) were coupled to carboxylated microspheres and lyophilized [25] . Pooled lyophilized microspheres were then reconstituted and incubated with plasma samples (1:80 dilution) for 3 hours in a microtiter plate with shaking at room temperature (RT). Detection was achieved with biotinylated anti-IgG (Pharminogen) followed by streptavidin-phycoerythrin (1 μg/ mL) and analyzed on a BioPlex 100 analyzer.
Plasmodium falciparum In Vitro Asexual/Gametocyte Cultures
Asexual P falciparum cultures (NF54 and 3D7A [MR4]) were maintained in continuous culture [27] and synchronized with 5% D-sorbitol treatments [28] (see Supplementary Methods). Plasmodium falciparum in vitro gametocyte cultures (NF54 strain) were induced and maintained according to published protocols [29] (see Supplementary Methods).
Plasmodium falciparum Protein Lysates
Plasmodium falciparum NF54 cultures were sorbitol-synchronized on day 1, with collection of lysates on days 2, 4, 6, 8, and 10 after addition of 50 mM N-acetyl-glucosamine (GlcNAc), (corresponding to stage I, II, III, IV, and V gametocytes, respectively). Gametocytes were purified using sorbitol synchronization and MACS-CS columns ([MACS] Miltenyi Biotec). Asexual P falciparum 3D7A cultures were collected at ring, trophozoite, and schizont stages. Solubilized protein lysates were prepared by standard methods (see Supplementary Methods). Plates were washed, incubated for 1 hour at RT with goat antihuman IgG-conjugated to alkaline phosphatase (Sigma) (1:1000), washed, and developed using p-nitrophenylphosphate tablets (Sigma). Absorbance was read at 405 nm.
Generation of Murine Polyclonal Antibodies to Purified Antigens
BALB/c mice (Charles River Laboratories) were immunized with 50 μg of each antigen emulsified in 100 μL TiterMax Gold adjuvant (Titermax) or adjuvant alone, and sera was collected as described elsewhere [19] (see Supplementary Methods). Antigen-affinity purified polyclonal, monospecific antibody was prepared in rabbits by GenScript (Piscataway, NJ).
Immunofluorescence Assays and Western Blots
Gametocyte antigens were immunolocalized in indirect immunofluorescence assays (IFAs) with stage-specific protein expression analyzed in Western blots. Positive control antibodies included anti-ring-infected erythrocyte surface antigen (RESA) for ring-stage parasites, anti-Pfs16 (MR4) and anti-MDV-1/PEG3 for early-and late-stage gametocytes, respectively, and anti-MSP-9 for asexual parasites. The IFAs and Western blots were performed according to standard methods (see Supplementary Methods).
Flow Cytometry
Flow cytometry was performed according to established protocols with NF54-strain P falciparum parasites and various antibodies on a MACSQuant Analyzer 10 (Miltenyi Biotec) flow cytometer (see Supplementary Methods). Data were analyzed using FlowJo software (TreeStar, Inc).
Statistical Analysis
We used generalized estimating equation (GEE)-based longitudinal regression models to determine whether IgG responses to candidate antigens measured at 2 weeks posttreatment predicted resistance to gametocytemia (Y/N) or gametocyte density (no. of gametocytes/200 white blood cells [WBCs]) on 18 weekly follow-up blood films. These GEE models allowed for repeated measures of the outcome and were evaluated for potential confounders such as age, hemoglobin phenotype, and asexual parasitemia. Potential confounders and effect modifiers, including age, hemoglobin phenotype (%AS), hemoglobin level, asexual parasitemia, and week of study, were evaluated and retained in the model if their P values were less than 0.1. Since the predictor (antibody responses) was dichotomized as detectible/nondetectible (defined as ≥ mean + 2 standard deviations [SD] of n = 15 North American controls), GEE models were constructed using Proc Genmod with a binomial link function. All modeling was performed in SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
Gametocyte Density Declines With Increasing Age
Intense transmission pressure in the study region resulted in a high cumulative prevalence of P falciparum parasitemia (79.0% [113 of 143]) in the cohort over the 18 weeks of follow up. Asexual reinfection peaked 1.5 months posttreatment (median, 5.5 weeks; interquartile range [IQR], 4 weeks) and was followed 5.5 weeks later by a wave of microscopically detectible gametocytemia (median, 11 weeks; IQR, 5 weeks). The cumulative prevalence of patent gametocytemia over the 18 weeks of follow-up was 39.9% (57 of 143). In GEE models, after controlling for asexual stage parasitemia, age was an independent predictor of gametocyte density measured on routine blood films in this cohort (P < .04). This relationship is consistent with naturally acquired antigametocyte immune responses developing over time in this study population.
Identification of Individuals With Resistance and Susceptibility to
Gametocytemia
Using mean gametocyte density quantified on the 18 posttreatment blood films [20, 21, 23, 24] , we identified and pooled plasma from the 10 most resistant (low RP) and 10 most susceptible (high SP) individuals after matching for potential confounding variables of age, hemoglobin phenotype (AA vs AS-sickle trait), hemoglobin level, asexual parasite density, frequency of asexual parasitemia, number of sulfadoxine-pyrimethamine doses, and mean week at which doses were administered (Table 1) . Because study participants were intermittently treated with sulfadoxine-pyrimethamine for febrile episodes over the follow-up period, we analyzed the relationship between gametocytemia and treatment intervals. A significant temporal relationship between gametocytemia and treatment interval was not detected in this cohort in GEE models (P = .232). 
Plasma Pooled From Resistant and Susceptible Individuals Recognizes Crude Gametocyte Antigens
To assess total IgG reactivity of RP and SP with the different gametocyte developmental stages, we performed enzymelinked immunosorbent assays with crude pooled asexual mixed-stage, sexual stage-specific, and uninfected red blood cell (RBC) lysates ( Figure 1 ). Antibody recognition of crude antigens prepared from all 5 gametocyte stages did not differ between resistant and susceptible groups (all P > .05, Student's t test), suggesting that susceptible individuals recognize many of the same gametocyte antigens as resistant individuals.
Identification of Antigametocyte Vaccine Candidates
Using RP and SP plasma, we performed a differential screen of a P falciparum 3D7 gametocyte stage cDNA expression library. We screened 563 000 clones, and we identified 428 clones that reacted with antibodies in both plasma groups, 25 clones that were uniquely reactive with antibodies in SP, and 13 clones that were uniquely reactive with antibodies in RP. These 13 clones encoded 8 unique genes. Clones uniquely reactive with RP along with 1 negative (nonreactive) and 1 positive control (dually reactive) clones were sequenced, and their identities were determined. The PlasmoDb Gene ID, select protein features and total number of single-nucleotide polymorphisms of uniquely reactive clones, along with positive and negative control clones are presented in Table 2 . The ORF of the antigens uniquely reactive with RP were codon harmonized for bacterial expression and cloned into the expression plasmid pD451-SR. A 10× His tag was added at the carboxy termini of each recombinant protein, to facilitate purification by metal chelate chromatography.
Expression, Purification, and Validation of Uniquely Recognized
Gametocyte Antigens
We optimized protein expression in the Escherichia coli cell line BL21(DE3) (Supplementary Figure S1) , and we used a 2-step chromatographic strategy (nickel-chelate > size exclusion chromatography) to purify recombinant antigens to >95% purity. We were able to express and purify 5 of the 8 identified antigens, corresponding to 2 antigenic fragments of Pf3D7_0506900 amino acids (aa)1-195 and aa101-195, Pf3D7_0411000 aa294-843, Pf3D7_1466200 aa1379-1687 (designated PfsEGXP-A, see below), Pf3D7_1021900 aa1082-1653, and Pf3D7_0924600 aa1-409. To quantify total IgG responses to the identified recombinant malarial proteins before whole-cohort validation, we probed antigens with RP and SP along with pooled plasma (n = 15) from North American malaria-naive controls with our multiplexed antigen-specific antibody assays [26] .
Antibodies to rPfsEGXP-A Predict Decreased Gametocyte Density and Longer Time to Patent Gametocytemia
To determine whether antibody responses to our vaccine candidates were associated with decreased gametocytemia in the whole cohort, we measured IgG levels to these recombinant proteins using fluorescent bead-based assays. We measured antigen-specific IgG in plasma obtained 2 weeks after treatment in our longitudinal Kenyan cohort (n = 143) and related these levels to subsequent gametocytemia assessed on weekly blood films obtained during 18 weeks of follow-up. Antibodies to Pf3D7_0506900, Pf3D7_0411000, Pf3D7_1466200, Pf3D7_ 1021900, and Pf3D7_0924600 were detectible in 67.3%, 31.8%, 68.8%, 51.4%, and 47.8% of these samples, respectively (with Table 1 ). In this multiplexed bead-based assay, recombinant antigens were coupled to microspheres, probed with plasma, and incubated in biotinylated total IgG-specific secondary reagents. After incubation with streptavidin-phycoerythrin, bound antibody was analyzed on a BioPlex 100 multiplexed analyzer. Bovine serum albumin (negative control) reactivity subtracted from all values: 10219 = Pf3D7_1021900 aa1082-1653, 14662 = Pf3D7_1466200 aa1379-1687 (pfs355-A), 9246 = Pf3D7_0924600 aa1-409, 5069 aa1-195 = Pf3D7_0506900 aa1-195, 5069 aa101-195 = Pf3D7_0506900 aa101-195, and 411 = Pf3D7_0411000 aa294-843. Bars represent the mean of duplicate wells performed in triplicate (n = 3; error bars = standard error of the mean). Abbreviation: aa, amino acids. responders defined as antibody levels ≥ mean total IgG + 2 SD of malaria-naive North American controls). Volunteers were followed for a cumulative total of 2484 weeks of follow-up observation.
In GEE models, antibodies measured at the start of the high-transmission season (ie, after treatment but before reinfection) to one of these antigens, Pf3D7_1466200 aa1379-1687, which we herein designate as rPfsEGXP-A (EGXP = "Early Gametocyte eXpressed Protein"), predicted significantly lower gametocytemia measured over the 18-week transmission season (P = .021) in study participants who developed gametocytemia (n = 57). Age (P = .024) and week of study (P = .0003) were additional variables retained in this final model that were both significantly associated with the outcome. When analyzed dichotomously in these repeated measures models, responders (n = 39) to rPfsEGXP-A had a 31% reduction in gametocyte density on gametocyte-positive smears over the follow-up period, compared with nonresponders (n = 18) after adjusting for important determinants of gametocyte density including age and asexual parasitemia (mean ± standard error, 123.0 ± 13.1 vs 86.6 ± 8.9 gametocytes/200 WBCs; P = .04) ( Figure 3A) . Modeling anti-rPfsEGXP-A total IgG responses as tertiles resulted in an inverse dose-response relationship between increasing anti-rPfsEGXP-A titers and declining gametocyte density that was significant when comparing low versus high tertiles (P = .011) after adjusting for critical determinants of gametocyte density including age and asexual parasitemia ( Figure 3B ). Cox proportional hazard analysis of time to patent gametocytemia in rPfsEGXP-A responders compared with nonresponders resulted in a modest but significant delay in the appearance of gametocytemia (P = .026) (hazard ratio = 0.51; 95% confidence interval = 0.28-0.92) ( Figure 3C) . A significant association between gametocyte density or time to patent gametocytemia and antibody response was not observed for the other antigens tested. In contrast to our results in individuals who developed gametocytemia (n = 57), when measured in the entire cohort including individuals who never developed gametocytemia, anti-rPfsEGXP-A antibodies did not predict decreased gametocyte density. This may reflect unmeasured, nonimmunologic factors that can influence gametocyte carriage rates such as unreported antimalarial drug use, ABO blood group [30] , and degree of reticulocytosis [31] .
PfsEGXP Is a Single-Copy Gene Unique to Plasmodium Species
In silico analysis of PfsEGXP reveals that the single exon 9237 base pairs gene (original annotation: Pf3D7_1466200 / PF14_0631) encodes a hypothetical 3078aa conserved protein of unknown function with a predicted molecular mass of 355 715 Da. Single syntenic orthologs are present in many (P falciparum IT, Plasmodium gaboni strain SY75) but not all (Plasmodium malariae UG01) of the primate, human, and rodent malarias evaluated. The NF54 ortholog (PfNF54_05780) surprisingly encodes a much smaller hypothetical protein of 1671aa (predicted molecular mass of 183 810 Da) that aligns with the N-terminal region of the 3D7 predicted product (Supplementary Figure S2) . Based on maximal expression of this protein in early stage gametocytes (see the following section), we designate the protein product of Pf3D7_1466200 as PfsEGXP and its corresponding gene as PfsEGXP. We designate the immunorelevant region of PfsEGXP that we identified in the library screen as PfsEGXP-A (Supplementary Figure S2) . PfsEGXP-A corresponds to aa 1378 to 1687 of the full-length PfsEGXP protein. Amino acid-based BLAST searches of GenBank sequences with full-length PfsEGXP also identified significant homology (95.7% similarity) with erythrocyte membrane-associated antigen (embl accession no. X53024.2), a 326 residue polypeptide (aa 1562-1884 of PfsEGXP) cloned from a P falciparum genomic DNA library screened with pooled immune sera from residents of an endemic area of Liberia [32] . Homology with nonplasmodial sequences was not present, indicating that the PfsEGXP protein is unique to Plasmodium. GenAutomated functional annotation of this protein by the extended similarity group method used by the Plasmodium Genomics resource [33] predicts that this phosphoprotein [34] may bind calcium ions.
PfsEGXP Protein Expression Detected in Early Stage, NF54-Strain
Gametocytes
In indirect IFAs, PfsEGXP protein expression is detected in the first 24 hours postinvasion in early ring-like stage gametocytes (stage specificity confirmed with anti-RESA antibodies that recognize both asexual and sexual ring stage parasites [35] , with asexual vs sexual identity discussed below) in a punctate pattern in close apposition to the erythrocyte membrane ( Figure 4 Figure S5 ) were enumerated yielding a gametocyte conversion rate of 9.6%. In NF54 and 3D7A strain asexual cultures, immunostaining of ring (NF54) (Supplementary Figure S6) or ring/ trophozoite (3D7A) asexual stages with mouse/rabbit anti-rPfsEGXP-A antibodies was not detectable above background (Supplementary Figure S7) . Stage specificity of our gametocyte culture IFAs were corroborated by published proteomic data [38] , transcriptional profiling [39] , and Western blot data (see Supplementary Figure S8 ). The IFA negative controls (preimmune sera) are presented in Supplementary Figure S9 
DISCUSSION
In our study, we sought to identify novel antigametocyte TBV candidate antigens using our whole-proteome differential screening approach with plasma collected from individuals who were resistant or susceptible to gametocytemia over a high-transmission season [18, 19] . We differentially screened a gametocyte stage cDNA expression library and identified a unique gametocyte antigen, PfsEGXP, which is the target of antibodies that predict decreased gametocytemia. Specifically, individuals with detectible anti-PfsEGXP at the start of the high-transmission season had a 31% reduction in gametocyte density and a modest delay in time to patent gametocytemia over 18 weeks of follow-up in a cohort of Kenyan adolescent males. Nano-liquid chromatography tandem mass spectrometric analysis of 3 parasite life-cycle stages followed by comparative analysis of protein abundance [38] indicates that PfsEGXP encodes a sexual stage-specific low abundance antigen-enriched in early I-II stage gametocytes. Evidence for the transcriptional activity of PfsEGXP in early gametocytes (0 to 20 hours postinvasion) is provided by a stage-specific transcriptional profiling study [39] , in which PfsEGXP clustered with a number of other genes such as GEXP04 [38] and puf1 [40] that are putatively expressed in these presequestration, circulating forms. Differential expression in male or female gametocytes remains to be determined. In a study that analyzed gametocyte sex-specific transcript expression of 87 gametocyte-specific genes using single cell ribonucleic acid sequencing [41] , PfsEGXP did not cluster with other male-or female-enriched genes evaluated. In regards to transcriptional regulation, the PfsEGXP gene may be under the control of PfAP2-G, a master regulator of sexual-stage development [42] , because a putative PfAP2-G binding site consensus sequence G(T,A,C)GTAC [43] was identified in 794 nucleotides upstream from the transcription start site.
Mass spectrometric-based expression evidence of this protein has been detected in phosphopeptide-enriched schizont samples [34] . Schizont expression is consistent with the results reported by Kun et al [32] , in which mouse antiserum raised against "erythrocyte membrane associated antigen, " a 322aa polypeptide contained within PfsEGXP, reacted with the membrane of air-dried, nonpermeabilized schizonts. We will evaluate the expression of this antigen in both sexually and nonsexually committed schizonts in future studies.
Because reagents to definitively characterize early ring-like stage gametocytes such as PfGEXP-5 [35] are scarce, an obvious caveat of this study is our inference of PfsEGXP-positive parasitized cells in day 1 gametocyte cultures (which typically contain early-ring-like stage gametocytes, trophozoites, and asynchronous rings [29] ) as sexual forms. To determine the commitment to early ring stage parasites to sexual versus asexual development, we analyzed the expression of PfsEGXP in NF54 cultures in which gametocytogenesis was induced versus not induced. Under standard conditions, NF54 parasites can spontaneously undergo an up to 2%-3% per cycle conversion to sexual development [44] , and this conversion rate increases to 10%-22% when gametocytogenesis is induced [29] . Under these contrasting culture conditions, <0.5% of ring stage parasites were recognized by anti-rPfsEGXP-A when grown under standard conditions (see Supplementary Figure S6 for representative IFA), whereas 11.6% of ring stage parasites were recognized by anti-rPfsEGXP-A when induced to commit to sexual development (data not shown). This is consistent with typical gametocyte conversion rates [45] observed in our laboratory (median, 14%; range, 6%-18%), which are enumerated from morphologically recognizable stage II-III gametocytes (day 4) (see Supplementary Figure S5 ) per total number of parasites in GlcNAc-treated, nonpurified cultures.
CONCLUSIONS
Functional characterization, further refinement of subcellular localization with electron microscopy, and characterization of the mode of action of anti-rPfsEGXP-A antibodies are all the focus of ongoing work. In conclusion, this work has identified one of the first gametocyte-specific antigens that is the target of antibodies that predict decreased gametocytemia in humans. We expect that further discovery efforts will identify additional gametocyte antigens that induce gametocyte controlling humoral responses, providing the framework for the development of an antigametocyte TBV for P falciparum.
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